Literature DB >> 10674397

Apoptosis mediated by activation of the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein (PTHrP).

P R Turner1, S Mefford, S Christakos, R A Nissenson.   

Abstract

The present studies were carried out to evaluate the mechanisms by which PTH/PTHrP receptor (PTHR) activation influences cell viability. In 293 cells expressing recombinant PTHRs, PTH treatment markedly reduced the number of viable cells. This effect was associated with a marked apoptotic response including DNA fragmentation and the appearance of apoptotic nuclei. Similar effects were evidenced in response to serum withdrawal or to the addition of tumor necrosis factor (TNFalpha). Addition of caspase inhibitors or overexpression of bcl-2 partially abrogated apoptosis induced by serum withdrawal. Caspase inhibitors also protected cells from PTH-induced apoptosis, but overexpression of bcl-2 did not. The effects of PTH on cell number and apoptosis were neither mimicked by activators of the cAMP pathway (forskolin, isoproterenol) nor blocked by an inhibitor (H-89). However, elevation of Ca(i)2+ by addition of thapsigargin induced rapid apoptosis, and suppression of Ca(i)2+ by overexpression of the calcium- binding protein, calbindin D28k, inhibited PTH-induced apoptosis. The protein kinase C inhibitor GF 109203X partially inhibited PTH-induced apoptosis. Regulator of G protein signaling 4 (RGS4) (an inhibitor of the activity of the alpha-subunit of Gq) suppressed apoptotic signaling by the PTHR, whereas the C-terminal fragment of GRK2 (an inhibitor of the activity of the beta(gamma)-subunits of G proteins) was without effect. Chemical mutagenesis allowed selection of a series of 293 cell lines resistant to the apoptotic actions of PTH; a subset of these were also resistant to TNFalpha. These results suggest that 1) apoptosis produced by PTHR and TNF receptor signaling involve converging pathways; and 2) Gq-mediated phospholipase C/Ca2+ signaling, rather than Gs-mediated cAMP signaling, is required for the apoptotic effects of PTHR activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674397     DOI: 10.1210/mend.14.2.0417

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  6 in total

Review 1.  Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine.

Authors:  Laurie K McCauley; T John Martin
Journal:  J Bone Miner Res       Date:  2012-05-01       Impact factor: 6.741

2.  Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects.

Authors:  Wei Yao; Zhiqiang Cheng; Mohammad Shahnazari; Wewei Dai; Mark L Johnson; Nancy E Lane
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

3.  Endogenous mono-ADP-ribosylation of the free Gbetagamma prevents stimulation of phosphoinositide 3-kinase-gamma and phospholipase C-beta2 and is activated by G-protein-coupled receptors.

Authors:  Rosita Lupi; Nadia Dani; Alexander Dietrich; Adriano Marchegiani; Sabrina Turacchio; Christopher P Berrie; Joel Moss; Peter Gierschik; Daniela Corda; Maria Di Girolamo
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

4.  Coherent expression chromosome cluster analysis reveals differential regulatory functions of amino-terminal and distal parathyroid hormone-related protein domains in prostate carcinoma.

Authors:  I Tsigelny; D W Burton; Y Sharikov; R H Hastings; L J Deftos
Journal:  J Biomed Biotechnol       Date:  2005

5.  EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca2.

Authors:  Yun Shan Chen; Fen Liu; Yi Hong Luo; Yue Fan; Fang Gui Xu; Pin Li; Bei Zhou; Xiu Yu Pan; Chi Chiu Wang; Long Cui
Journal:  Cancer Manag Res       Date:  2019-08-05       Impact factor: 3.989

6.  Protective effects of calbindin‑D28K on the UVB radiation‑induced apoptosis of human lens epithelial cells.

Authors:  Kang Liu; Jianfeng Zhao; Liushu Yang; Meng Guan; Ling Yuan; Yu Geng
Journal:  Int J Mol Med       Date:  2020-03-26       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.